Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

64 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Dietary Inulin to Improve SARS-CoV-2 Vaccine Response in Kidney Transplant Recipients: The RIVASTIM-Inulin Randomised Controlled Trial.
Singer J, Tunbridge MJ, Shi B, Perkins GB, Chai CS, Salehi T, Sim BZ, Kireta S, Johnston JK, Akerman A, Milogiannakis V, Aggarwal A, Turville S, Hissaria P, Ying T, Wu H, Grubor-Bauk B, Coates PT, Chadban SJ. Singer J, et al. Among authors: salehi t. Vaccines (Basel). 2024 Jun 3;12(6):608. doi: 10.3390/vaccines12060608. Vaccines (Basel). 2024. PMID: 38932337 Free PMC article.
Immune Checkpoint Inhibitors in Recipients of Renal Allografts.
Venkataraman K, Salehi T, Carroll RP. Venkataraman K, et al. Among authors: salehi t. Semin Nephrol. 2024 Jan;44(1):151500. doi: 10.1016/j.semnephrol.2024.151500. Epub 2024 Mar 27. Semin Nephrol. 2024. PMID: 38548484 Review.
Rituximab Resistance in Glomerular Diseases: A GlomCon Mini Review.
Salehi T, Krishnan A, Al Jurdi A, So P, Lerma E, Wiegley N; GlomCon Editorial Team. Salehi T, et al. Kidney Med. 2024 Feb 16;6(4):100791. doi: 10.1016/j.xkme.2024.100791. eCollection 2024 Apr. Kidney Med. 2024. PMID: 38495600 Free PMC article.
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial.
Rovin BH, Barratt J, Heerspink HJL, Alpers CE, Bieler S, Chae DW, Diva UA, Floege J, Gesualdo L, Inrig JK, Kohan DE, Komers R, Kooienga LA, Lafayette R, Maes B, Małecki R, Mercer A, Noronha IL, Oh SW, Peh CA, Praga M, Preciado P, Radhakrishnan J, Rheault MN, Rote WE, Tang SCW, Tesar V, Trachtman H, Trimarchi H, Tumlin JA, Wong MG, Perkovic V; DUPRO steering committee and PROTECT Investigators. Rovin BH, et al. Lancet. 2023 Dec 2;402(10417):2077-2090. doi: 10.1016/S0140-6736(23)02302-4. Epub 2023 Nov 3. Lancet. 2023. PMID: 37931634 Clinical Trial.
64 results